Literature DB >> 8070022

Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.

W T Beck1, R Kim, M Chen.   

Abstract

We review herein current work on the cytotoxic and cellular actions of two classes of inhibitors of DNA topoisomerase II: one represented by etoposide and teniposide, which stabilize DNA-protein complexes, and another represented by merbarone and aclarubicin, which do not stabilize such complexes. We discuss current concepts of protooncogene activation and cell cycle perturbations by some of these inhibitors and summarize recent findings of novel actions of the latter compounds in tumor cells that express a mutant topoisomerase II.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8070022     DOI: 10.1007/bf00684858

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  38 in total

Review 1.  A model for tumor cell killing by topoisomerase poisons.

Authors:  H Zhang; P D'Arpa; L F Liu
Journal:  Cancer Cells       Date:  1990-01

Review 2.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

Review 3.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

4.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

5.  Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.

Authors:  E Solary; R Bertrand; K W Kohn; Y Pommier
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

6.  Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.

Authors:  M J Robinson; N Osheroff
Journal:  Biochemistry       Date:  1990-03-13       Impact factor: 3.162

7.  Inhibition of type II topoisomerase by fostriecin.

Authors:  T J Boritzki; T S Wolfard; J A Besserer; R C Jackson; D W Fry
Journal:  Biochem Pharmacol       Date:  1988-11-01       Impact factor: 5.858

8.  In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.

Authors:  F H Drake; G A Hofmann; S M Mong; J O Bartus; R P Hertzberg; R K Johnson; M R Mattern; C K Mirabelli
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

9.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24.

Authors:  J R Jenkins; P Ayton; T Jones; S L Davies; D L Simmons; A L Harris; D Sheer; I D Hickson
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

View more
  4 in total

1.  Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.

Authors:  J Cummings; I Meikle; J S Macpherson; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.

Authors:  Y Matsumoto; K Kunishio; S Nagao
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-07

4.  Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.

Authors:  Y Matsumoto; H Takano; K Kunishio; S Nagao; T Fojo
Journal:  Jpn J Cancer Res       Date:  2001-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.